Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Systemic Lupus Erythematosus (SLE) involves severe, multi-organ flares, with Neuropsychiatric SLE (NPSLE) being a critical complication. We report a compelling case in a 20-year-old male where NPSLE developed de novo after the commencement of initial high dose immunosuppressive therapy for a pathologically complex lupus flare.
The patient was admitted with an active SLE flare presenting with nephrotic syndrome (UACR 13,867 mg/g; initial Urea 102 mg/dL), severe anemia (Hb 7.2 g/dL), and massive hemorrhagic pleural effusion (evacuation of 2250 cc). Initial serology confirmed high activity (ANA 1:400; low C3/C4), and management was complicated by refractory hypoalbuminemia (Albumin 2.2 g/dL, dropping to 1.9 g/dL). Kidney biopsy confirmed Focal Lupus Nephritis Class III (ISN/RPS) (Activity Index 7/24). Initial induction (Day 1-3) was Methylprednisolone (MP) pulse (250 mg/day). Crucially, the patient was neurologically intact at admission. However, on Day 7 of hospitalization, the patient developed acute NPSLE (incoherent speech).
Due to the emergence of NPSLE, a second, sequential course of MP pulse therapy (3 days x 250 mg/day) was immediately administered as salvage treatment, along with Risperidone (1x0.5 mg). This aggressive intervention led to a complete and rapid resolution of the neuropsychiatric symptoms. Upon 1-month follow-up post-discharge, the patient demonstrated a dramatic renal response: UACR decreased significantly to 523.03 mg/g, with normalization of renal function (Urea 28.1 mg/dL, Creatinine 0.6 mg/dL).
This case highlights the potential for new, life-threatening SLE manifestations (NPSLE) to emerge during the acute treatment phase of other severe flares (LN Class III). The successful and rapid reversal of NPSLE symptoms, coupled with demonstrable renal improvement, achieved with the sequential second MP pulse regimen validates this strategy as a critical, effective approach for managing the evolving spectrum of severe lupus.
